Coeptis Therapeutics Holdings, Inc.
COEP
$13.21
-$0.445-3.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 89.80% | 97.22% | -25.41% | -58.11% | -32.29% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.96% | 40.98% | -35.76% | -72.89% | -23.25% |
| Operating Income | -59.87% | -38.82% | 35.76% | 72.89% | 23.25% |
| Income Before Tax | -42.81% | -13.98% | 19.81% | 71.20% | 5.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.81% | -13.98% | 19.81% | 71.20% | 5.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.45% | -1.88% | 48.13% | 71.20% | 5.22% |
| EBIT | -59.87% | -38.82% | 35.76% | 72.89% | 23.25% |
| EBITDA | -63.93% | -40.77% | 38.63% | 75.28% | 24.95% |
| EPS Basic | 40.99% | 41.08% | 57.18% | 80.72% | 44.98% |
| Normalized Basic EPS | 42.48% | 45.28% | 75.61% | 81.11% | 44.98% |
| EPS Diluted | 40.99% | 41.08% | 57.18% | 80.72% | 44.98% |
| Normalized Diluted EPS | 42.48% | 45.28% | 75.61% | 81.11% | 44.98% |
| Average Basic Shares Outstanding | 97.33% | 72.92% | 21.13% | 49.37% | 72.28% |
| Average Diluted Shares Outstanding | 97.33% | 72.92% | 21.13% | 49.37% | 72.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |